Matthew Matasar, MD, Oncology, New York, NY, Memorial Sloan-Kettering Cancer Center

MatthewJMatasarMD

Oncology New York, NY

Hematologic Oncology

Chief of Medical Oncology, MSK Bergen; Assistant Member, Lymphoma Service; Director, Lymphoma Survivorship Clinic

Dr. Matasar is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Matasar's full profile

Already have an account?

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFELLOWSHIP
  • New York Presbyterian Hospital -  Columbia Campus
    New York Presbyterian Hospital - Columbia CampusRESIDENCY
  • Harvard Medical School
    Harvard Medical SchoolMEDICAL_SCHOOL

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2018 - 2021
  • NY State Medical License
    NY State Medical License 2003 - 2022

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
    Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
    Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
    Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Res... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Practice Pearl 1: The Benefits of a Flat Dose
    Practice Pearl 1: The Benefits of a Flat DoseOctober 11, 2019
  • Roche’s Combo Lymphoma Treatment Wins U.S. FDA Approval
    Roche’s Combo Lymphoma Treatment Wins U.S. FDA ApprovalJune 14, 2019

Hospital Affiliations